Development and validation of risk prediction tools for pressure injury occurrence: An umbrella review

Bethany Hillier[1,2]

Katie Scandrett[1,2]

April Coombe[1,2]

Tina Hernandez-Boussard[3]

Ewout Steyerberg[4]

Yemisi Takwoingi[1,2]

Vladica Velickovic[5,6]

Jacqueline Dinnes[1,2*]

Affiliations

[1] Biostatistics, Evidence Synthesis, Test Evaluation And Prediction Modelling (BESTEAM), Institute of Applied Health Research, University of Birmingham, Edgbaston, Birmingham, UK

[2] NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, UK

[3] Department of Medicine, Stanford University, Stanford, CA USA

[4] Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands

[5] Evidence Generation Department, HARTMANN GROUP, Heidenheim, Germany

[6] Institute of Public Health, Medical, Decision Making and Health Technology Assessment, UMIT, Hall, Tirol, Austria

Email addresses

b.hillier@bham.ac.uk (BH); k.e.scandrett@bham.ac.uk (KS); a.r.coombe@bham.ac.uk (AC); boussard@stanford.edu (THB); e.w.steyerberg@lumc.nl (ES); y.takwoingi@bham.ac.uk (YT); vladica.velickovic@hartmann.info (VV)

* Corresponding author: j.dinnes@bham.ac.uk (JD)

Keywords

Development, internal, external validation, prediction, prognostic, pressure injury, ulcer, overview

ABSTRACT

Background

Pressure injuries (PIs) place a substantial burden on healthcare systems worldwide. Risk stratification of those who are at risk of developing PIs allows preventive interventions to be focused on patients who are at the highest risk. The considerable number of risk assessment scales and prediction models available underscore the need for a thorough evaluation of their development, validation and clinical utility.

Our objectives were to identify and describe available risk prediction tools for PI occurrence, their content and development and validation methods used.

Methods

The umbrella review was conducted according to Cochrane guidance. MEDLINE, Embase, CINAHL, EPISTEMONIKOS, Google Scholar and reference lists were searched to identify relevant systematic reviews. Risk of bias was assessed using adapted AMSTAR-2 criteria. Results were described narratively. All included reviews contributed to build a comprehensive list of risk prediction tools.

Results

We identified five systematic reviews describing the development and validation of risk prediction tools for pressure injuries, 16 that assessed the prognostic accuracy of the tools and 10 that assessed the clinical effectiveness. Of the five reviews of model development and validation, four included only machine learning models. One review included detail about external validation, and this was the only review to include model performance metrics. Where quality assessment was completed (3 out of 5 reviews), most prediction tools were assessed by review authors as being at high risk of bias and no tools were assessed as being at low risk of bias.

Conclusions

Available tools do not meet current standards for the development or reporting of risk prediction models. The majority of tools have not been externally validated. Standardised and rigorous approaches to risk prediction model development and validation are needed.

Registration

The protocol was registered on the Open Science Framework (https://osf.io/tepyk).

INTRODUCTION

Pressure injuries (PI) carry a significant healthcare burden. A recent meta-analysis estimated the global burden of PIs to be 13%, two-thirds of which are hospital-acquired PIs (HAPI).[1] The average cost of a HAPI has been estimated as $11k per patient, totalling at least $27 billion a year in the United States based on 2.5 million reported cases.[2] Length of hospital stay is a large contributing cost, with patients over the age of 75 who develop HAPI having on average a 10-day longer hospital stay compared to those without PI.[3]

PIs result from prolonged pressure, typically on bony areas like heels, ankles, and the coccyx, and are more common in those with limited mobility, including those who are bedridden or wheelchair users. PIs can develop rapidly, and pose a threat in community, hospital and long-term care settings. Multicomponent preventive strategies are needed to reduce PI incidence[4] with timely implementation to both reduce harm and burden to healthcare systems.[5] Where preventive measures fail or are not introduced in adequate time, PI treatment involves cleansing, debridement, topical and biophysical agents, biofilms, growth factors and dressings[6 7 8], and in severe cases, surgery may be necessary.[5 9]

A number of clinical assessment scales for assessing the risk of PI are available (e.g. Braden[10 11], Norton[12], Waterlow[13]) but are limited by reliance on subjective clinical judgment. Statistical risk prediction models may offer improved accuracy over clinical assessment scales, however appropriate methods of development and validation are required.[14 15 16] Although methods for developing risk prediction models have developed considerably,[14 15 17 18] methodological standards of available models have been shown to remain relatively low.[17 19-22] Machine learning (ML) algorithms to develop prediction models are increasingly commonplace, but these models are at similarly high risk of bias[23] and do not necessarily offer any model performance benefit over the use of statistical methods such as logistic regression.[24] Methods for systematic reviews of risk prediction model studies have also improved,[25-27] with tools such as PROBAST (Prediction model Risk of Bias Assessment Tool)[28] now available to allow critical evaluation of study methods.

Although several systematic reviews of PI risk assessment scales and risk prediction models for PI (subsequently referred to as risk prediction tools) are available[29-38], these have been demonstrated to frequently focus on single or small numbers of scales or models, use variable review methods and show a lack of consensus about the accuracy and clinical effectiveness of available tools.[39] We conducted an umbrella review of systematic reviews of risk prediction tools for PI to gain further insight into the methods used for tool development and validation, and to summarise the content of available tools.

METHODS

Protocol registration and reporting of findings

We followed guidance for conducting umbrella reviews provided in the Cochrane Handbook for Intervention Reviews.[40] The review was reported in accordance with guidelines for Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)[41] (see Appendix 1), adapted for risk prediction model reviews as required. The protocol was registered on the Open Science Framework (https://osf.io/tepyk).

Literature search

A single sensitive search strategy, developed and tested by an experienced information specialist (AC), was conducted in January 2023. Electronic searches of MEDLINE and Embase via Ovid and

CINAHL Plus EBSCO were conducted, employing well-established systematic review and prognostic search filters[42-44] combined with specific keyword and controlled vocabulary terms relating to PI appropriate to each source, without restrictions on publication year. Additional simplified searches were undertaken in EPISTEMONIKOS and Google Scholar due to the more limited search functionality of these two sources. The reference lists of all publications reporting reviews of prediction tools (systematic or non-systematic) were reviewed to identify additional eligible systematic reviews and to populate a list of PI risk prediction tools. Title and abstract screening and full text screening were conducted independently and in duplicate by two of four reviewers (BH, JD, YT, KS). Any disagreements were resolved by discussion or referral to a third reviewer.

Eligibility criteria for this umbrella review

Published English-language systematic reviews of risk prediction models developed for adult patients at risk of PI in any setting were included. Reviews of clinical risk assessment tools or models developed using statistical or ML methods were included, both with or without internal or external validation. The use of any PI classification system[6 45-47] as a reference standard was eligible. Reviews of the diagnosis or staging of those with suspected or existing PIs or chronic wounds, reviews of prognostic factor and predictor finding studies, and models exclusively using pressure sensor data were excluded.

Systematic reviews were required to report a comprehensive search of at least two electronic databases, and at least one other indicator of systematic methods (i.e. explicit eligibility criteria, formal quality assessment of included studies, sufficient data presented to allow results to be reproduced, or review stages (e.g. search screening) conducted independently in duplicate.

Data extraction and quality assessment

Data extraction forms (Appendix 3) were developed using the CHARMS checklist (CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies) and Cochrane Prognosis group template.[48 49] One reviewer extracted data concerning: review characteristics, model details, number of studies and participants, study quality and results. Extractions were independently checked by a second reviewer. Where discrepancies in model or primary study details were noted between reviews, we accessed the primary model development publications where possible.

The methodological quality of included systematic reviews was assessed using AMSTAR-2 (A Measurement Tool to Assess Systematic Reviews)[50], adapted for systematic reviews of risk prediction models (Appendix 4). Quality assessment and data extraction were conducted by one reviewer and checked by a second (BH, JD, KS), with disagreements resolved by consensus. Our adapted AMSTAR-2 contains six critical items, and limitations in any of these items reduces the overall validity of a review.[50]

Synthesis methods

Reviews were considered according to whether any information concerning model development and validation were reported. Available data were tabulated and a narrative synthesis provided. All risk prediction models identified are listed in Appendix 5 Table S4, including those for which no information about model development or validation was provided at systematic review level. Where possible, the predictors included in the tools were extracted at review level and categorised into relevant groups in order to describe the candidate predictors associated with risk of PI. No statistical synthesis of systematic review results was conducted. Reviews reporting results as prognostic accuracy (i.e. risk classification according to a binary decision) or clinical effectiveness (i.e. impact on patient management and outcomes) are reported elsewhere.[39]

RESULTS

Characteristics of included reviews

Following de-duplication of search results, 6301 unique records remained, of which 110 were selected for full text assessment. We obtained the full text of 104 publications of which 28 met all eligibility criteria for inclusion (see Figure 1). Five reviews reported details about model development and internal validation[36 37 51-53], one of which also considered external validation[52]; 16 reported accuracy data[29 31-35 38 54-62]; and 10 reported clinical effectiveness data.[30 54 56 59 63-68] Three reviews reported both accuracy and effectiveness data.[54 56 59]

Table 1 provides a summary of systematic review methods for all 28 reviews according to whether or not they reported any tool development methods (see Appendix 5 for full details). The five reviews reporting prediction tool development and validation were all published within the last five years (2019 to 2023) compared to reviews focused on the clinical utility of available tools (published from 2006 to 2022). Reviews about tool development focused primarily on ML-based models (one[58] of the five reviews limited inclusion to empirically derived models including ML-based models, and four (80%) considered only ML models) and frequently did not report study eligibility criteria related study participants or setting. Only one review (4%) concerning the clinical utility of models included ML-based models,[38] but more often restricted study inclusion by population or setting: hospital inpatients (ward or acute unit) (n = 4),[33 38 63 67] acute settings (n=5),[34 59 61 62 66] or surgical patients (n=1)[31], or studies in long-term care settings (n=2)[29 35] or the elderly (n=1).[58]

On average reviews about tool development included more studies than reviews of clinical utility (median 22 compared to 13), more participants (median 234,105 compared to 6,106) and covered more prediction tools (median 21 compared to 3) (Table 1). Eight reviews (35%) about clinical utility included only one risk assessment scale, whereas reviews of tool development included at least 3 different risk prediction models. The PROBAST tool for quality assessment of prediction model studies was used in 60% (n=3) of tool development reviews[37 52 53] compared to none of the reviews of clinical utility, however the remaining two reviews of tool development did not report any quality assessment of included studies (2 (40%) compared to 4 (17%) of reviews of clinical utility). Meta-analysis was conducted in one of five (20%) reviews of tool development compared to more than half of reviews of clinical utility (13, 57%).

Methodological quality of included reviews

The quality of included reviews was generally low (Figure 2; Appendix 5 for detailed assessments). The majority of reviews (all five reviews about tool development and 70% (16/23) reviews of clinical utility) partially met the AMSTAR-2 criteria for the literature search (i.e. searched two databases, reported search strategy or key words, and justified language restrictions if used), with only two (both reviews of clinical utility) meeting all criteria for 'Yes' (i.e. searching grey literature and reference lists, with the search conducted within 2 years of publication). Nineteen reviews (68%) conducted study selection in duplicate (4/5 (80%) of review about tool development and 15/23 (65%) of clinical utility reviews). Conflicts of interest were reported in all five tool development reviews and 74% of clinical utility reviews (17/23). Reviews scored poorly on the remaining AMSTAR-2 items, with at most half of reviews meeting the stipulated AMSTAR-2 criteria. Seven reviews (25%) used an appropriate method of quality assessment of included studies and provided itemisation of judgements per study. No review scored 'Yes' for all AMSTAR-2 items in either category.

195 *Figure 1. PRISMA[41] flowchart: identification, screening and selection process*



196 *List of full-text articles excluded, with reasons, is given in Appendix 5.*

197 *Table 1. Summary of included systematic review characteristics*

Review characteristics	Reviews on model development and validation (N=5)	Reviews on accuracy or clinical effectiveness (N=23)	All included reviews (N=28)
Median (range) year of publication	2021 (2019 – 2023)	2016 (2006 – 2022)	2018 (2006 – 2023)
Eligibility criteria			
Participants			
Adults only	0 (0)	13 (57) [A]	13 (46) [A]
Any age	0 (0)	3 (13)	3 (11)
No age restriction reported	5 (100)	7 (30)	12 (43)
Presence of PI at baseline			
No PIs at baseline	0 (0)	6 (26)	6 (21)
NS	5 (100)	17 (74)	22 (79)
Setting			
Any healthcare setting	0 (0)	10 (43)	10 (36)
Hospital	1 (20)	4 (22)	5 (18)
Long-term care	0 (0)	2 (9)	2 (7)
Acute care (incl. surgical and ICU)	0 (0)	6 (26)	6 (21)
Long-term, acute or community settings	0 (0)	1 (4)	1 (4)
NS	4 (80)	0 (0)	4 (14)
Risk assessment tools			
ML-based prediction models	4 (80)	1 (4)	5 (18)
ML or statistical models	1 (20)	0 (0)	1 (4)
Any prediction tool or scale	0 (0)	9 (39)	9 (32)
Specified clinical scale(s)	0 (0)	10 (43)	10 (36)
PI prevention strategies	0 (0)	1 (4)	1 (4)
NS	0 (0)	2 (9)	2 (7)
PI classification system			
Any	0 (0)	1 (4)	1 (4)
Accepted standard classifications	0 (0)	2 (9)	2 (7)
Several specified classification systems (NPUAP, EPUAP, AHCPR or TDCPS)	0 (0)	3 (13)	3 (11)
Other	0 (0)	1 (4)	1 (4)
NS	5 (100)	16 (70)	21 (75)
Source of data			
Prospective only	0 (0)	4.5 (20) [B]	4.5 (16) [B]
Prospective or retrospective	1 (20)	2.5 (11) [B]	3.5 (13) [B]
NS	4 (80)	16 (70)	20 (71)
Study design restrictions			
Yes	1 (20)	12 (52)	13 (46)
No	0 (0)	3 (13)	3 (11)
NS	4 (80)	8 (39)	12 (43)
Review methods			
Median (range) no. sources[C] searched	5 (2 – 8)	6 (2 – 14)	5 (2 – 14)
Publication restrictions:			
End date (year)			
2000-2009	0 (0)	3 (13)	3 (11)
2010-2019	1 (20)	16 (70)	17 (61)
2020-2023	4 (80)	4 (17)	8 (29)
Language			
English only	4 (80)	9 (39)	13 (46)
2 languages	0 (0)	2 (9)	2 (7)
>2 languages	0 (0)	3 (13)	3 (11)
No restrictions	0 (0)	4 (17)	4 (14)
NS	1 (20)	5 (22)	6 (21)

Quality assessment tool [D]			
PROBAST	3 (60)	0 (0) [E]	3 (11) [E]
QUADAS	0 (0)	2 (9)	2 (7)
QUADAS-2	0 (0)	7 (30)	7 (25)
JBI tools	0 (0)	3 (13)	3 (11)
CASP	0 (0)	2 (9)	2 (7)
Other	0 (0)	6 (26)	6 (21)
None	2 (40)	4 (17)	6 (21)
Meta-analysis included	1 (20)	13 (57)	14 (50)
Method of meta-analysis (% of reviews incl. meta-analysis)			
Univariate RE/FE model (depending on heterogeneity assessment)	1 (100) [F]	2 (15) [F]	3 (21)
Univariate RE model	0 (0)	5 (38) [F]	5 (36) [F]
Hierarchical model (for DTA studies)	0 (0)	2 (15)	2 (14)
Unclear/NS	0 (0)	4 (31) [F]	4 (29) [F]
Volume of evidence			
Median (range) no. studies	22 (3 – 35)	13 (1 – 70)	16 (1 – 70)
Median (range) no. participants	234105 (6674 – 1278148)	6106 (528 – 221541)	10044 (528 – 1278148)
Median (range) no. tools	21 (3 – 35)	3 (1 – 28)	4 (1 – 35)

Figures are number (%) of reviews, unless otherwise specified. [A] one review[58] restricted to aged >60 years; [B] one review [54] states either prospective or retrospective data eligible for Research Question 1, but prospective only for Research Question 2, hence 0.5 added to each category; [C] including databases, bibliographies or registries; [D] reviews may fall into multiple categories, therefore total number within domain not necessarily equal to N (100%); [E] one review[38] reported use of PROBAST in methods, but did not present any PROBAST results; [F] one review conducts univariate meta-analysis for a single estimate, e.g. c-statistic[52], AUC[60], RR[55], or OR.[56]

AHCPR – Agency for Health Care Policy and Research; CASP – Critical Appraisal Skills Programme; DTA – diagnostic test accuracy; EPUAP – European Pressure Ulcer Advisory Panel; FE – fixed effects; ICU – intensive care unit; JBI – Joanna Briggs Institute; ML – machine learning; NPUAP – National Pressure Ulcer Advisory Panel; NS – not stated; PI – pressure injury; PROBAST – Prediction model Risk of Bias Assessment; QUADAS (2) – Quality Assessment of Diagnostic Accuracy Studies (Version 2); RE – random effects; TDCPS – Torrance Developmental Classification of Pressure Sore.

Figure 2. Summary of AMSTAR-2 assessment results



AMSTAR – A MeaSurement Tool to Assess systematic Reviews; Item 1 – Adequate research question/ inclusion criteria?; Item 2 – Protocol and justifications for deviations?; Item 3 – Reasons for study design inclusions?; Item 4 – Comprehensive search strategy?; Item 5 – Study selection in duplicate?; Item 6 – Data extraction in duplicate?; Item 7 – Excluded studies list (with justifications)?; Item 8 – Included studies description adequate?; Item 9 – Assessment of RoB/quality satisfactory?; Item 10 – Studies' sources of funding reported?; Item 11 – Appropriate statistical synthesis method?; Item 12 – Assessment of impact of RoB on synthesised results?; Item 13 – Assessment of impact of RoB on review results?; Item 14 – Discussion/investigation of heterogeneity?; Item 15 – Conflicts of interest reported?; N/A – not applicable; RoB – risk of bias; QA – quality assessment. Further details on AMSTAR items are given in Appendix 4, and results per review are given in Appendix 5. Note that where AMSTAR-2 assessment was applied to overlapping reviews (n=3) for prognostic accuracy and clinical effectiveness separately, and resulted in differing judgements for each review question, the judgements for the prognostic accuracy review question are displayed here for simplicity.

217 *Table 2. Results of reviews reporting model development and validation*

Review author (publication year)	DEV/ VAL (no. studies)	Setting of included studies; data sources	Model development algorithms	Internal validation method	Brief description of study quality	Summary of model performance results
Dweekat[36] (2023)	DEV (34); unclear (1)[A]	HAPI/CAPI n=32; SRPI n=2; detection of PI (effect on length of stay) n=1; nursing home residents n=2	LR n=20; RF n=18; DT n=12; SVM n=12; MLP n=9; KNN n=4; LDA n=1; other n=19	CV n=10; split sample n=10; split sample and CV n=8; NS=7	No RoB assessment	N/A
Jiang[37] (2021)	DEV (9)	ICU n=3; operating room n=2; acute care hospital n=1; oncology department n=1; end-of-life care n=1; mobility-related disabilities n=1 EHRs used in all models	DT n=5; LR n=3; SVM n=2; NN n=2; RF n=1; MTS n=1; BN n=1; gradient boosting n=1	Split sample n=4; NS n=9	RoB assessed using PROBAST. Overall RoB high for all predictive models. All models at high RoB in analysis domain.	F-score ranged between 0.377 (ML Su MTS) and 0.670 (ML Su LR); g-means ranged between 0.628 (ML Kaewprag BN) and 0.822 (ML Su MTS); sensitivity ranged between 0.478 (ML Kawprag) and 0.848 (ML Yang); specificity ranged between 0.703 (ML Deng) and 0.988 (ML Su LR)
Ribeiro[51] (2021)	DEV (3)	SRPI cardiovascular n=2; SRPI critical care n=1 EHRs used in n=2 models	ANN n=1; XGBoost n=1; RF n=1	Split sample n=2; NS n=1	No RoB assessment	N/A
Shi[52] (2019)	DEV (21); VAL (7)	*DEV* General acute care hospital n=7; long-term care n=5; specific acute care (e.g. ICU) n=4; cardiovascular surgery n=2; trauma and burn centres n=1; rehabilitation units n=1; unclear n=1 Prospective n=10; retrospective n=11 *VAL* Long-term care n=3; specific acute care (e.g. ICU) n=2; general (acute care) hospital n=2	LR n=16; cox regression n=5; ANN n=1; DT n=1; discriminant analysis n=1; C4.5 machine learning (DT induction algorithm) n=1; NS n=1	CV n=1; tree-pruning n=1; split sample n=1; re-sampling n=2; NS n=16	RoB assessed using PROBAST. *DEV* Overall RoB unclear for two models. Overall RoB high for the remaining 19 models. Analysis and outcome domains were mostly at high RoB. *VAL* Overall RoB unclear for three validation studies. Overall RoB high for the remaining four validation studies. Analysis and outcome domains were mostly at high RoB.	C-statistics[B] ranged between 0.61 (interRAI PURS) and 0.90 (TNH-PUPP); O/E ratios[B] ranged between 0.91 (Berlowitz MDS) and 1.0 (prePURSE study tool) *Pooled C-statistics*[B] TNH-PUPP: 0.86 (95% CI 0.81–0.90), n=2 Fragmment scale: 0.79 (95% CI 0.77–0.82), n=1[C] Berlowitz 11-item model: 0.75 (95% CI 0.74–0.76), n=2 Berlowitz MDS model: 0.73 (95% CI 0.72–0.74), n=2 interRAI PURS: 0.65 (95% CI 0.60–0.69), n=3 Compton: 0.81 (95% CI 0.78–0.84), n=2 *Pooled O/E ratios*[B] 0.99 (95% CI 0.95–1.04), n=2

Review author (publication year)	DEV/ VAL (no. studies)	Setting of included studies; data sources	Model development algorithms	Internal validation method	Brief description of study quality	Summary of model performance results
		Prospective n=3; retrospective n=4				Berlowitz MDS 0.94 (95% CI 0.88–1.01), n=2
Zhou[53] (2022)	DEV (22)	SRPI n=3; ICU n=11; hospitalised n=6; rehabilitation centre n=1; hospice n=1 EHR n=18; Medical Information Mart for Intensive care III database n=4	LR n=15; RF n=10; DT n=9; SVM; n=9; ANN n=8; BN n=3; XGBoost n=3; GB n=2; AdaBoost n=1; CANTRIP n=1; LSTM n=1; EN n=1; KNN n=1; MTS n=1; NB n=1	CV n=12; NS n=10	RoB assessed using PROBAST. Overall RoB unclear for five studies. Overall RoB high for 15 models. RoB not assessed in two studies due to use of unstructured data.	F1 score ranged between 0.02 (ML Nakagami) and 0.99 (ML Song [2]); AUC ranged between 0.78 (ML Delparte) and 0.99 (ML Song [2]); sensitivity tanged between 0.08 (ML Cai) and 0.99 (ML Song [2]); specificity ranged between 0.63 (ML Delparte) and 1 (ML Cai)

[A] Appears to be a model validation study but the review only included model development studies.
[B] Values from fixed-effects meta-analyses, pooling development and external validation study estimates together.
[C] One data source but included two C-statistic values (one for model development and one for internal validation) that were subsequently pooled.

AUC – area under curve; ANN – artificial neural network; BN – Bayesian network; CAPI – community-acquired pressure injury; CANTRIP - reCurrent Additive Network for Temporal RIsk Prediction; CV – cross-validation; DEV – development; DT – decision tree; EHRs – electronic health records; EN – elastic net; GB – gradient boosting; HAPI – hospital-acquired pressure injury; ICU – intensive care unit; KNN – k-nearest neighbours; LDA – linear discriminant analysis; LSTM – long short-term memory; LR – logistic regression; ML – machine learning; MLP – multilayer perception; MTS – Mahalanobis-Taguchi system; N/A – not applicable; NB – naïve Bayes; NN – neural network; O/E – observed vs expected; PI – pressure injury; PROBAST – Prediction model Risk of Bias ASsessment Tool; RF – random forest; RoB – risk of bias; SRPI – surgery-related pressure injury; SVM – support vector machine; VAL – validation.

Findings

Of the 28 reviews, 23 reviews focused on the clinical utility of prediction tools provided no details about the development or validation of included models (see Appendix 5), and gave only limited detail about setting and study design. These reviews included a total of 63 different prediction tools, predominantly derived by clinical experts, as opposed to empirically-derived models. The most commonly included tools were the Braden (included in 20 reviews), Waterlow (n=14 reviews), Norton (n=11 reviews), and Cubbin and Jackson scales (n=8 reviews).

The five systematic reviews that reported detailed information about model development and validation included 62 prediction models, 40 of which were unique to these five reviews (between one[37] and 20[52] unique models were included per review) (Table 2). Between three[51] and 35[36] model development studies were included; one review[52] also included 7 external validation studies. Electronic health records (EHRs) were used for model development in all studies in one review[37] and in 18 of 22 models (82%) in a second review.[53] One review[52] reported the use of prospectively or retrospectively collected data (n=10 studies and n=11 studies, respectively). No review included information about the thresholds used define whether a patient is at risk of developing PIs. Four reviews included detail about the predictors included in each model.

The largest review[36] reported that logistic regression was the most commonly reported modelling approach (20/35 models), followed by random forest (n=18), decision tree (n=12) and support vector machine (n=12) approaches. Logistic regression was also the most frequently used in two other reviews (16/21[52] and 15/22[53]). Primary studies frequently compared the use of different ML methods using the same datasets, such that 'other' ML methods were reported with little to no further detail (e.g. 19 studies in the review by Dweekat and colleagues[36]).

Approaches to internal validation were not well reported in the primary studies. One review[52] found no information on internal validation for 76% (16/21) of studies; with re-sampling reported in two and tree-pruning, cross-validation and split sample reported in one study each. Another[36] reported no information about internal validation for 20% of studies (7/35) and the use of cross-validation (n=10), split sample (n=10) techniques, or both (n=8) for the remainder. Cross-validation was used in more than half (12/22) of studies in another.[53] Only one review reported any detail about methods for selection of model predictors[52]: 29% (6/21) selected predictors by univariate analysis prior to modelling and 9 used stepwise selection for final model predictors; 11 (52%) clearly reported candidate predictors, and all 21 clearly reported final model predictors. The same review[52] reported 15 models (71%) with no information about missing data, and only two using imputation techniques.

Model performance measures were reported by three reviews[37 52 53], all of which noted considerable variation in reported metrics and model performance including C-statistics (0.71 to 0.89 in 10 studies[53]), F1 score (0.02 to 0.99 in 9 studies[53]), G-means (0.628 to 0.822 in four studies[37]), and observed versus expected ratios (0.97 to 1 in 3 studies[52]). Two reviews reported accuracy metrics associated with included models: sensitivity ranged between 0.48 and 0.85 and specificity between 0.70 and 0.99 for 7 models in one review,[37] compared to sensitivity 0.08 to 0.99 (for 19 studies[52]) and specificity 0.63 to 1.00 (for 18 studies[52]) in another. AUC ranged between 0.78 and 0.99 for 16 studies[52].

Shi and colleagues[52] included 7 external validations using data from long-term care (n=3) or acute hospital care (n=4) settings. All were judged to be at unclear (n=3) or high (n=4) risk of bias using PROBAST. Model performance metrics for five models (TNH-PUPP[69], Berlowitz 11-item model[70], Berlowitz MDS adjustment model[71], interRAI PURS[72], Compton ICU model[73]) included C-statistics between 0.61 and 0.9 and reported observed versus expected ratios were between 0.91 and 0.97.

The review also reported external validation studies for the 'SS scale' and the prePURSE study tool, but no model performance metrics were given. A meta-analysis of C-statistics and O/E ratios was performed, including values from both development and external validation cohorts (Table 2). Parameters related to model development were not consistently reported: C-statistics ranged between 0.71 and 0.89 (n = 10 studies); observed versus expected ratios ranged between 0.97 and 1 (n=3 studies). For more detailed information about individual models, including predictors, specific model performance metrics and sample sizes (Appendix 5).

Included tools and predictors

A total of 116 risk prediction tools were identified (Table 3); 103 were identified from the 28 included systematic reviews and 13 were identified from screening the reference lists of the 'non-systematic' reviews that were considered during full text assessment. Full details obtained at review-level are reported in Appendix 5 Table S4.

Tools were categorised as having been developed with (52/116, 45%) or without (64, 55%) the use of ML methods. Prospectively collected data was used for model development for 19% of tools (22/116), retrospectively collected data for 40% (46/116), including 18 ML-based models using EHRs, or was not reported (48/116). Information about the study populations was poorly reported, however study setting was reported for 102 prediction tools. Thirty-four tools were reported to have been developed in hospital inpatients, and 20 were developed in long-term care settings, rehabilitation units or nursing homes or hospices. Where reported (n=92), sample sizes ranged from 15[74] to 1,252,313.[75-82] The approach to internal validation used for the prediction tools (e.g. cross-validation versus split sample) was not reported at review-level for almost three quarters of tools (81/116, 70%).

We could extract information about the predictors for only 53 of the 116 tools (Table 4 and Appendix 5). The most frequently included predictor was mobility (27/53, 51%), followed by pre-disposing diseases/conditions (26/53, 49%), medical treatment/care received (22/53, 42%) and continence (22/53, 42%). Tools often (23/53, 45%) included multiple pre-existing conditions or comorbidities and multiple types of treatment or medication as predictors. Other common predictors include age, nutrition, mental status, activity, skin conditions and laboratory values (34% to 40% of models). Seven tools incorporated scores from other established risk prediction scales as a predictor, with six including Braden scores and one including the Norton score.

Only one review[52] reported the presentation format of included tools, coded as 'score system' (n=11), 'formula equation' (n=3), 'nomogram scale' (n=2), or 'not reported' (n=6).

305 *Table 3. Summary of tool characteristics, extracted at review-level*

Tool characteristics	ML-based models (N=52, 45%)	Non-ML tools (N=64, 55%)	Total (N=116)
No. of included reviews[A] considered in			
0	0 (0)	13 (20)	13 (11)
1	30 (58)	23 (36)	53 (46)
2	8 (15)	9 (14)	17 (15)
>2	14 (27)	19 (30)	33 (28)
Development study details			
Median (range) year of publication	2020 (2000 – 2022)	1998 (1962 – 2015)	2006 (1962 – 2022)
Source of data			
Prospective	4 (8)	18 (28)	22 (19)
Retrospective	36 (69)	10 (16)	46 (40)
NS	12 (23)	36 (56)	48 (41)
Setting			
Hospital	13 (25)	11 (17)	24 (21)
Long-term care (incl. end-of-life and rehab)	6 (12)	14 (22)	20 (17)
Acute care (incl. surgical and ICU)	28 (54)	24 (38)	52 (45)
Mixed settings	1 (2)	1 (2)	2 (2)
Other	2 (4)	2 (3)	4 (3)
NS	2 (4)	12 (19)	14 (12)
Study population age			
Adults	31 (60)	34 (53)	65 (56)
Any	5 (10)	3 (5)	8 (7)
NS	16 (31)	27 (42)	43 (37)
Baseline condition			
PIs at baseline	1 (2)	0 (0)	1 (1)
No PIs at baseline	11 (21)	19 (30)	30 (26)
NS	40 (77)	45 (70)	85 (73)
Development methods			
Development method/algorithm[B]			
ML algorithms	52 (100)	0 (0)	52 (45)
Logistic regression	35 (67)	15 (23) [C]	50 (43)
Cox regression	0 (0)	5 (8)	5 (4)
Clinical expertise	0 (0)	2 (3)	2 (2)
NS	0 (0)	44 (69) [D]	44 (38)
Internal validation method			
Cross-validation	21 (40)	3 (5) [G]	24 (21)
Data splitting	11 (21)	0 (0)	11 (9)
Not done / NS	20 (38) [F]	61 (95)	81 (70)
Median (range) no. of final predictors[E]	6 (3 – 23)	8 (2 – 15)	7 (2 – 23)
Study cohort			
Median (range) total sample size	3000 (27 – 1252313)	320 (15 – 31150)	686 (15 – 1252313)
Median (range) number of events	206 (8 – 86410)	51 (9 – 1350)	94 (8 – 86410)
Median (range) proportion of events (% of sample size)	10.65% (0.42% – 80.00%)	14.84% (1.18% – 46.67%)	14.40% (0.42% – 80.00%)

306 *[A] the 28 included systematic reviews; [B] tools use multiple methods, therefore total number not equal to N (100%); [C] one*
307 *study also used discriminant analysis for model development; [D] many seemed to use clinical expertise, but development*
308 *methods were not clearly reported; [E] counting of final predictors may vary between models: some* authors *may count*
309 *individual factors, while others consider domains or subscales; [F] one review[36] implies 5 models did not implement internal*
310 *validation; [G] 'resampling' (not described further) was used for the development of 2 models; ML – machine learning; NS –*
311 *not stated; ICU – intensive care unit; PI – pressure injury.*

312

Table 4. Predictor categories and frequency (%) of inclusion in N=53 models.

Predictor category	No. of tools predictor appears in
Mobility	27 (51)
Pre-disposing conditions	26 (49)
Continence	22 (42)
Receiving medical treatment/care	22 (42)
Age	21 (40)
Mental Status	20 (38)
Nutrition	20 (38)
Activity	19 (36)
Laboratory values	18 (34)
Skin	18 (34)
General Health	16 (30)
Body	13 (25)
Gender	11 (21)
Surgery duration	7 (13)
Ability to ambulate	6 (11)
Braden score	6 (11)
Pressure injury	6 (11)
Friction, shear, pressure	5 (9)
Medical unit, ward, visit	5 (9)
Length of stay	4 (8)
Hygiene	3 (6)
Ethnicity	2 (4)
Pain	2 (4)
Smoking	2 (4)
'Special' (not explained)	2 (4)
Isolation	1 (2)
Norton score	1 (2)

Figures are given as count (% out of 53 tools with information on predictors). Note that multiple predictors may fall within the same predictor category. For instance, the category 'skin' may encompass both 'skin moisture' and 'skin integrity', with the frequency count reflecting the entire predictor category rather than individual predictors.

DISCUSSION

This umbrella review summarises data from 28 eligible systematic reviews of PI risk prediction tools. Quality assessment using an adaptation of AMSTAR-2 revealed that most reviews were conducted to a relatively poor standard. Critical flaws were identified, including inadequate or absent reporting of protocols (23/28, 82%), inappropriate meta-analysis methods (11/15, 73%) and lack of consideration for risk of bias judgements when discussing review results (14/28, 50%). Despite the large number of risk prediction models identified, only five reviews focused on the development and validation of predominantly ML-based prediction models. The remaining reviews aimed to summarise evidence for the accuracy (sensitivity and specificity) or effectiveness of identified models. For many (44/64, 69%) prediction tools that were developed without the use of ML, we were not able to determine whether reliable and robust statistical methods were used or whether models were essentially risk assessment tools developed based on expert knowledge. For over half (63/116, 54%) of the identified tools, predictors included in the final models were not reported. Details of study populations and settings were also lacking. It was not always clear from the reviews whether the poor reporting occurred at review level or in the original primary study publications.

A recent systematic review of risk of bias in machine learning developed prediction models found that most models are of poor methodological quality and are at high risk of bias.[23] In our set of reviews, of the three reviews that conducted a risk of bias assessment using the PROBAST tool, all models were found to be at high or unclear risk of bias.[52]

Where the method of internal validation was reported, split-sample and cross-validation were the most commonly used techniques, however, detail was limited, and it was not possible to determine whether appropriate methods had been used. Although split-sample approaches have been favoured for model validation, more recent empirical work suggests that bootstrap-based optimism correction[83] or cross-validation[84] are preferred approaches. None of the included reviews reported the use of optimism correction approaches.

Model development algorithms included logistic regression, decision trees and random forests, with a vast number of ML-based models having been developed in the last five years. In contrast to logistic regression approaches, decision trees and random forests while providing valuable risk classification, may not give a proper risk probability. Instead, they commonly categorise patients into binary 'at risk' or 'not at risk' groups. Although the risk probabilities generated in logistic regression prediction models can be useful for clinical decision making, it was not possible to derive any information about thresholds used to define 'at risk' or 'not at risk', and for most reviews, it was unclear what the final model comprised of. This lack of transparency poses potential hurdles in applying these models effectively in clinical settings.

Only one review included external validations of previously developed models[52], however limited details of model performance were presented. External validation is necessary to ensure a model is both reproducible and generalisable[85 86], bringing the usefulness of the models included in these reviews into question. The PROGRESS framework suggests that multiple external validation studies should be conducted using independent datasets from different locations.[15] In the only review that included model validation studies[52], it is unclear whether these studies were conducted in different locations, and all were conducted in the same setting. PROGRESS also suggests that external validations are carried out in a variety of relevant settings. Four out of eight validations were described as using 'temporal' data, which suggests that the validation population is largely the same as the development population but with use of data from different timeframes. This approach has been described as 'between' internal and external validation, further emphasising the need for well-designed external validation studies.[85] Furthermore, none of the eight external validations reported model recalibration. Recent evidence suggests focus should be placed on large, well-designed external validation studies to validate and improve promising models (using recalibration and updating[87]), rather than developing a multitude of new ones.[18 15] Model validation and recalibration should be a continuous process, and this is something that future research should address. Following external validation, the PROGRESS framework[15] suggests that effectiveness studies should be conducted following external validation to assess the effect of the model on decision making, patient outcomes and costs.

Despite the advances in methods for developing risk prediction models, scales developed using clinical expertise such as the Braden Scale, Norton Scale, Waterlow Score and Cubbin-Jackson Scale are extensively discussed in numerous clinical practice guidelines for patient risk assessment, and are commonly used in clinical practice.[6 88] Although guidelines recognise their low accuracy, they are still acknowledged, while other risk prediction models are not even considered. This may be due to the availability of at least some clinical trials evaluating the clinical utility of scales.[39] Some scales, such as the Braden scale, are so widely used that they have become an integral component of risk assessment for PI in clinical practice, and have even been incorporated into EHRs. Their widespread use may impede the progress towards development, validation and evaluation of more accurate and innovative risk prediction models. Striking a balance between tradition and embracing advancements is crucial for effective implementation in healthcare settings and improving patient outcomes.

Other existing evidence

We are aware of one additional systematic review of ML prediction models for PIs published after our search was conducted.[89] Pei and colleagues included 18 models, all of which were already included in our list of identified models. The aim of the review was to assess risk factors related to HAPIs, rather than assess tools to predict PIs and only ML-based models were included. A meta-analysis was conducted by pooling prognostic accuracy measures across all models that provided 2x2 data (n=14 models). The pooled AUC across the 14 models was 0.94, pooled sensitivity was 0.79 (95% CI 0.78–0.80) and pooled specificity was 0.87 (95% CI 0.88–0.87).[89] A meta-regression was conducted to investigate whether these values differed by machine learning algorithm; no difference based on algorithm was found. Review authors found 16/18 studies at high risk of bias based on PROBAST. We had low confidence in the review itself, through applying our adapted AMSTAR-2 criteria; one critical flaw was their use of inappropriate meta-analysis methods (not using a hierarchical model for pooling sensitivity and specificity).

Strengths and limitations

Our umbrella reviews were conducted to a high standard, following Cochrane guidance[40], and with a highly sensitive search strategy designed by an experienced information specialist. Although we excluded non-English publications due to time and resource constraints, where possible these publications were used to identify additional eligible risk prediction models. To some extent our review is limited by the use of AMSTAR-2 for quality assessment of included reviews. AMSTAR-2 was not designed for assessment of diagnostic or prognostic studies and, although we made some adaptations, many of the existing and amended criteria relate to the quality of reporting of the reviews as opposed to methodological quality. There is scope for further work to establish criteria for assessing systematic reviews of prediction models.

The main limitation, however, was the lack of detail about risk prediction models and risk prediction model performance that could be determined from the included systematic reviews. To be as comprehensive as possible in model identification, we were relatively generous in our definition of 'systematic', and this may have contributed to the often poor level of detail provided by included reviews. It is likely, however, that reporting was poor in many of the primary studies contributing to these reviews. Excluding the ML-based models, more than half of available risk prediction scales or tools were published prior to the year 2000. The fact that the original versions of reporting guidelines for diagnostic accuracy studies[90] and risk prediction models[91] were not published until 2003 and 2015 respectively, is likely to have contributed to poor reporting. In contrast, the ML-based models were published between 2000 and 2022, with a median year of 2020. Reporting guidelines for development and validation of ML-based models are more recent[92] or still in development[93], but aim to improve the reporting standards and understanding of evolving ML technologies in healthcare.

CONCLUSIONS

There is a very large body of evidence reporting various risk prediction scales, tool and models for PI which has been summarised across multiple systematic reviews of varying methodological quality. Only five systematic reviews reported the development and validation of models to predict risk of PIs. It seems that for the most part, available models do not meet current standards for the development or reporting of risk prediction models. Furthermore, most available models, including ML-based models have not been validated beyond the original population in which they were developed. Identification of the optimal risk prediction model for PI from those currently available would require a high-quality systematic review of the primary literature, ideally limited to studies

426 conducted to a high methodological standard. It is evident from our findings that there is still a lack
427 of consensus on the optimal risk prediction model for PI, highlighting the need for more standardised
428 and rigorous approaches in future research.

429

Acknowledgements

We would like to thank Mrs. Rosie Boodell (University of Birmingham, UK) for her help in acquiring the publications necessary to complete this piece of work.

Author Contributions

Conceptualisation: Bethany Hillier, Katie Scandrett, April Coombe, Tina Hernandez-Boussard, Ewout Steyerberg, Yemisi Takwoingi, Vladica Velickovic, Jacqueline Dinnes

Data curation: Bethany Hillier, Katie Scandrett, April Coombe, Jacqueline Dinnes

Formal analysis: Bethany Hillier, Katie Scandrett, Jacqueline Dinnes

Funding acquisition: Yemisi Takwoingi, Vladica Velickovic, Jacqueline Dinnes

Investigation: Bethany Hillier, Katie Scandrett, April Coombe, Yemisi Takwoingi, Jacqueline Dinnes

Methodology: Bethany Hillier, Katie Scandrett, April Coombe, Tina Hernandez-Boussard, Ewout Steyerberg, Yemisi Takwoingi, Vladica Velickovic, Jacqueline Dinnes

Project administration: Bethany Hillier, Yemisi Takwoingi, Jacqueline Dinnes

Resources: Bethany Hillier, Katie Scandrett

Supervision: Yemisi Takwoingi, Jacqueline Dinnes

Writing – original draft: Bethany Hillier, Katie Scandrett, April Coombe, Jacqueline Dinnes

Writing – review & editing: Bethany Hillier, Katie Scandrett, April Coombe, Tina Hernandez-Boussard, Ewout Steyerberg, Yemisi Takwoingi, Vladica Velickovic, Jacqueline Dinnes

Funding

This work was commissioned and supported by Paul Hartmann AG (Heidenheim, Germany). The contract with the University of Birmingham was agreed on the legal understanding that the authors had the freedom to publish results regardless of the findings.

YT, JD, BH, KS and AC are funded by the National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre (BRC). This paper presents independent research supported by the NIHR Birmingham BRC at the University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.

Conflicting Interests

The authors of this manuscript have the following competing interests: VV is an employee of Paul Hartmann AG; ES and THB received consultancy fees from Paul Hartmann AG. All other authors received no personal funding or personal compensation from Paul Hartmann AG and have declared that no competing interests exist.

References

1. Li Z, Lin F, Thalib L, et al. Global prevalence and incidence of pressure injuries in hospitalised adult patients: A systematic review and meta-analysis. *International Journal of Nursing Studies* 2020;105:103-546. doi: 10.1016/j.ijnurstu.2020.103546
2. Padula WV, Delarmente BA. The national cost of hospital-acquired pressure injuries in the United States. *Int Wound J* 2019;16(3):634-40. doi: 10.1111/iwj.13071 [published Online First: 2019/01/28]
3. Theisen S, Drabik A, Stock S. Pressure ulcers in older hospitalised patients and its impact on length of stay: a retrospective observational study. *J Clin Nurs* 2012;21(3-4):380-7. doi: 10.1111/j.1365-2702.2011.03915.x [published Online First: 2011/12/09]
4. Sullivan N, Schoelles K. Preventing In-Facility Pressure Ulcers as a Patient Safety Strategy. *Annals of Internal Medicine* 2013;158(5.2):410-16. doi: 10.7326/0003-4819-158-5-201303051-00008
5. Institute for Quality and Efficiency in Health Care (IQWiG). Preventing pressure ulcers. Cologne, Germany 2006 [updated 2018 Nov 15. Available from: https://www.ncbi.nlm.nih.gov/books/NBK326430/?report=classic accessed Feb 2023].
6. Haesler E. European Pressure Ulcer Advisory Panel, National Pressure Injury Advisory Panel and Pan Pacific Pressure Injury Alliance. Prevention and Treatment of Pressure Ulcers/Injuries: Clinical Practice Guideline. 2019 [Available from: https://internationalguideline.com/2019 accessed Feb 2023].
7. Walker RM, Gillespie BM, McInnes E, et al. Prevention and treatment of pressure injuries: A meta-synthesis of Cochrane Reviews. *Journal of Tissue Viability* 2020;29(4):227-43. doi: 10.1016/j.jtv.2020.05.004
8. Shi C, Dumville JC, Cullum N, et al. Beds, overlays and mattresses for preventing and treating pressure ulcers: an overview of Cochrane Reviews and network meta-analysis. *Cochrane Database Syst Rev* 2021;8(8):Cd013761. doi: 10.1002/14651858.CD013761.pub2 [published Online First: 2021/08/16]
9. Russo CA, Steiner C, Spector W. Hospitalizations Related to Pressure Ulcers, 2006. HCUP Statistical Brief: Agency for Healthcare Research and Quality, Rockville, MD. 2008.
10. Braden B, Bergstrom N. A Conceptual Schema for the Study of the Etiology of Pressure Sores. *Rehabilitation Nursing* 1987;12(1):8-16. doi: 10.1002/j.2048-7940.1987.tb00541.x
11. Bergstrom N, Braden BJ, Laguzza A, et al. The Braden Scale for Predicting Pressure Sore Risk. *Nurs Res* 1987;36(4):205-10.
12. Norton D. Geriatric nursing problems. *Int Nurs Rev* 1962;9:39-41.
13. Waterlow J. Pressure sores: a risk assessment card. *Nursing Times* 1985;81:49-55.
14. Steyerberg EW, Harrell FE, Jr. Prediction models need appropriate internal, internal-external, and external validation. *J Clin Epidemiol* 2016;69:245-7. doi: 10.1016/j.jclinepi.2015.04.005 [published Online First: 2015/04/18]
15. Steyerberg EW, Moons KGM, van der Windt DA, et al. Prognosis Research Strategy (PROGRESS) 3: Prognostic Model Research. *PLOS Medicine* 2013;10(2):e1001381. doi: 10.1371/journal.pmed.1001381
16. Siontis GCM, Tzoulaki I, Castaldi PJ, et al. External validation of new risk prediction models is infrequent and reveals worse prognostic discrimination. *Journal of Clinical Epidemiology* 2015;68(1):25-34. doi: 10.1016/j.jclinepi.2014.09.007
17. Bouwmeester W, Zuithoff NPA, Mallett S, et al. Reporting and Methods in Clinical Prediction Research: A Systematic Review. *PLOS Medicine* 2012;9(5):e1001221. doi: 10.1371/journal.pmed.1001221
18. Van Calster B, Steyerberg EW, Wynants L, et al. There is no such thing as a validated prediction model. *BMC Medicine* 2023;21(1):70. doi: 10.1186/s12916-023-02779-w
19. Wynants L, Calster BV, Collins GS, et al. Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal. *BMJ* 2020;369:m1328. doi: 10.1136/bmj.m1328

20. Ma J, Dhiman P, Qi C, et al. Poor handling of continuous predictors in clinical prediction models using logistic regression: a systematic review. *J Clin Epidemiol* 2023;161:140-51. doi: 10.1016/j.jclinepi.2023.07.017 [published Online First: 2023/08/02]
21. Dhiman P, Ma J, Qi C, et al. Sample size requirements are not being considered in studies developing prediction models for binary outcomes: a systematic review. *BMC Medical Research Methodology* 2023;23(1):188. doi: 10.1186/s12874-023-02008-1
22. Moriarty AS, Meader N, Snell KIE, et al. Predicting relapse or recurrence of depression: systematic review of prognostic models. *Br J Psychiatry* 2022;221(2):448-58. doi: 10.1192/bjp.2021.218
23. Andaur Navarro CL, Damen JAA, Takada T, et al. Risk of bias in studies on prediction models developed using supervised machine learning techniques: systematic review. *BMJ* 2021;375:n2281. doi: 10.1136/bmj.n2281
24. Christodoulou E, Ma J, Collins GS, et al. A systematic review shows no performance benefit of machine learning over logistic regression for clinical prediction models. *J Clin Epidemiol* 2019;110:12-22. doi: 10.1016/j.jclinepi.2019.02.004 [published Online First: 20190211]
25. Debray TPA, Damen JAAG, Snell KIE, et al. A guide to systematic review and meta-analysis of prediction model performance. *BMJ* 2017;356:i6460. doi: 10.1136/bmj.i6460
26. Riley RD, van der Windt D, Croft P, et al. Prognosis research in healthcare: concepts, methods, and impact: Oxford University Press 2019.
27. Snell KIE, Levis B, Damen JAA, et al. Transparent reporting of multivariable prediction models for individual prognosis or diagnosis: checklist for systematic reviews and meta-analyses (TRIPOD-SRMA). *BMJ* 2023;381:e073538. doi: 10.1136/bmj-2022-073538
28. Wolff RF, Moons KGM, Riley RD, et al. PROBAST: A Tool to Assess the Risk of Bias and Applicability of Prediction Model Studies. *Annals of Internal Medicine* 2019;170(1):51-58. doi: 10.7326/M18-1376
29. Chen HL, Shen WQ, Liu P. A Meta-analysis to Evaluate the Predictive Validity of the Braden Scale for Pressure Ulcer Risk Assessment in Long-term Care. *Ostomy/wound management* 2016;62(9):20-8.
30. Baris N, Karabacak BG, Alpar SE. The Use of the Braden Scale in Assessing Pressure Ulcers in Turkey: A Systematic Review. *Advances in skin & wound care* 2015;28:349-57. doi: 10.1097/01.ASW.0000465299.99194.e6
31. He W, Liu P, Chen HL. The Braden Scale cannot be used alone for assessing pressure ulcer risk in surgical patients: a meta-analysis. *Ostomy/wound management* 2012;58:34-40.
32. Huang C, Ma Y, Wang C, et al. Predictive validity of the braden scale for pressure injury risk assessment in adults: A systematic review and meta-analysis. *Nursing open* 2021;8:2194-207. doi: 10.1002/nop2.792
33. Park SH, Choi YK, Kang CB. Predictive validity of the Braden Scale for pressure ulcer risk in hospitalized patients. *Journal of Tissue Viability* 2015;24:102-13. doi: 10.1016/j.jtv.2015.05.001
34. Wei M, Wu L, Chen Y, et al. Predictive Validity of the Braden Scale for Pressure Ulcer Risk in Critical Care: A Meta-Analysis. *Nursing in critical care* 2020;25:165-70. doi: 10.1111/nicc.12500
35. Wilchesky M, Lungu O. Predictive and concurrent validity of the Braden scale in long-term care: A meta-analysis. *Wound Repair and Regeneration* 2015;23:44-56. doi: 10.1111/wrr.12261
36. Dweekat OY, Lam SS, McGrath L. Machine Learning Techniques, Applications, and Potential Future Opportunities in Pressure Injuries (Bedsores) Management: A Systematic Review. *International journal of environmental research and public health* 2023;20(1) doi: 10.3390/ijerph20010796
37. Jiang M, Ma Y, Guo S, et al. Using Machine Learning Technologies in Pressure Injury Management: Systematic Review. *JMIR Medical Informatics* 2021;9(3):e25704. doi: 10.2196/25704

38. Qu C, Luo W, Zeng Z, et al. The predictive effect of different machine learning algorithms for pressure injuries in hospitalized patients: A network meta-analyses. *Heliyon* 2022;8(11):e11361. doi: 10.1016/j.heliyon.2022.e11361
39. Hillier B, Scandrett K, Coombe A, et al. Accuracy and clinical effectiveness of risk prediction tools for pressure injury occurrence: An umbrella review (pre-print). *MedRxiv* 2024 doi: TBC (UPDATE ME)
40. Pollock M, Fernandes RM BL, Pieper D, Hartling L,. Chapter V: Overviews of Reviews. In: Higgins JPT TJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA ed. Cochrane Handbook for Systematic Reviews of Interventions version 63 (updated February 2022). Available from www.training.cochrane.org/handbook: Cochrane 2022.
41. Moher D, Liberati A, Tetzlaff J, et al. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLOS Medicine* 2009;6(7):e1000097. doi: 10.1371/journal.pmed.1000097
42. Ingui BJ, Rogers MA. Searching for clinical prediction rules in MEDLINE. *J Am Med Inform Assoc* 2001;8(4):391-7. doi: 10.1136/jamia.2001.0080391 [published Online First: 2001/06/22]
43. Wilczynski NL, Haynes RB. Optimal Search Strategies for Detecting Clinically Sound Prognostic Studies in EMBASE: An Analytic Survey. *Journal of the American Medical Informatics Association* 2005;12(4):481-85. doi: 10.1197/jamia.M1752
44. Geersing G-J, Bouwmeester W, Zuithoff P, et al. Search Filters for Finding Prognostic and Diagnostic Prediction Studies in Medline to Enhance Systematic Reviews. *PLOS ONE* 2012;7(2):e32844. doi: 10.1371/journal.pone.0032844
45. NHS. Pressure ulcers: revised definition and measurement. Summary and recommendations 2018 [Available from: https://www.england.nhs.uk/wp-content/uploads/2021/09/NSTPP-summary-recommendations.pdf accessed Feb 2023].
46. AHCPR. Pressure ulcer treatment. : Agency for Health Care Policy and Research 1994:1-25.
47. Harker J. Pressure ulcer classification: the Torrance system. *Journal of Wound Care* 2000;9(6):275-77. doi: 10.12968/jowc.2000.9.6.26233
48. Moons KGM, de Groot JAH, Bouwmeester W, et al. Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies: The CHARMS Checklist. *PLOS Medicine* 2014;11(10):e1001744. doi: 10.1371/journal.pmed.1001744
49. Cochrane. DE form example prognostic models - scoping review: The Cochrane Collaboration: The Prognosis Methods Group; [Available from: https://methods.cochrane.org/prognosis/tools accessed Feb 2023].
50. Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. *BMJ* 2017;358:j4008. doi: 10.1136/bmj.j4008
51. Ribeiro F, Fidalgo F, Silva A, et al. Literature review of machine-learning algorithms for pressure ulcer prevention: Challenges and opportunities: MDPI 2021.
52. Shi C, Dumville JC, Cullum N. Evaluating the development and validation of empirically-derived prognostic models for pressure ulcer risk assessment: A systematic review. *International journal of nursing studies* 2019;89:88-103. doi: 10.1016/j.ijnurstu.2018.08.005
53. Zhou Y, Yang X, Ma S, et al. A systematic review of predictive models for hospital-acquired pressure injury using machine learning. *Nursing open* 2022;30 doi: 10.1002/nop2.1429
54. Chou R, Dana T, Bougatsos C, et al. Pressure ulcer risk assessment and prevention: a systematic comparative effectiveness review. *Annals of internal medicine* 2013;159(1):28-38.
55. García-Fernández FP, Pancorbo-Hidalgo PL, Agreda JJS. Predictive Capacity of Risk Assessment Scales and Clinical Judgment for Pressure Ulcers: A Meta-analysis. *Journal of Wound Ostomy & Continence Nursing* 2014;41(1):24-34. doi: 10.1097/01.WON.0000438014.90734.a2
56. Pancorbo-Hidalgo PL, Garcia-Fernandez FP, Lopez-Medina IM, et al. Risk assessment scales for pressure ulcer prevention: a systematic review. *J Adv Nurs* 2006;54(1):94-110. doi: 10.1111/j.1365-2648.2006.03794.x

57. Park SH, Lee HS. Assessing Predictive Validity of Pressure Ulcer Risk Scales- A Systematic Review and Meta-Analysis. *Iranian journal of public health* 2016;45(2):122-33.
58. Park SH, Lee YS, Kwon YM. Predictive Validity of Pressure Ulcer Risk Assessment Tools for Elderly: A Meta-Analysis. *Western journal of nursing research* 2016;38:459-83. doi: 10.1177/0193945915602259
59. Tayyib NAH, Coyer F, Lewis P. Pressure ulcers in the adult intensive care unit: a literature review of patient risk factors and risk assessment scales. *Journal of Nursing Education and Practice* 2013;3(11):28-42.
60. Wang N, Lv L, Yan F, et al. Biomarkers for the early detection of pressure injury: A systematic review and meta-analysis. *Journal of Tissue Viability* 2022;31:259-67. doi: 10.1016/j.jtv.2022.02.005
61. Zhang Y, Zhuang Y, Shen J, et al. Value of pressure injury assessment scales for patients in the intensive care unit: Systematic review and diagnostic test accuracy meta-analysis. *Intensive & critical care nursing* 2021;64:103009. doi: 10.1016/j.iccn.2020.103009
62. Zimmermann GS, Cremasco MF, Zanei SSV, et al. Pressure injury risk prediction in critical care patients: an integrative review. *Texto & Contexto-Enfermagem* 2018;27(3)
63. Gaspar S, Peralta M, Marques A, et al. Effectiveness on hospital-acquired pressure ulcers prevention: a systematic review. *International Wound Journal* 2019;16(5):1087-102. doi: 10.1111/iwj.13147
64. Ontario HQ. Pressure ulcer prevention: an evidence-based analysis. *Ontario health technology assessment series* 2009;9(2):1-104.
65. Kottner J, Dassen T, Tannen A. Inter- and intrarater reliability of the Waterlow pressure sore risk scale: A systematic review. *International Journal of Nursing Studies* 2009;46:369-79. doi: 10.1016/j.ijnurstu.2008.09.010
66. Lovegrove J, Ven S, Miles SJ, et al. Comparison of pressure injury risk assessment outcomes using a structured assessment tool versus clinical judgement: A systematic review. *Journal of Clinical Nursing* 2021 doi: 10.1111/jocn.16154 [published Online First: 2021/12/01]
67. Lovegrove J, Miles S, Fulbrook P. The relationship between pressure ulcer risk assessment and preventative interventions: a systematic review. *Journal of wound care* 2018;27(12):862-75.
68. Moore ZEH, Patton D. Risk assessment tools for the prevention of pressure ulcers. *Cochrane Database of Systematic Reviews* 2019 doi: 10.1002/14651858.CD006471.pub4
69. Page KN, Barker AL, Kamar J. Development and validation of a pressure ulcer risk assessment tool for acute hospital patients. *Wound Repair and Regeneration* 2011;19(1):31-37. doi: 10.1111/j.1524-475X.2010.00647.x
70. Berlowitz DR, Ash AS, Brandeis GH, et al. Rating long-term care facilities on pressure ulcer development: Importance of case-mix adjustment. *Annals of Internal Medicine* 1996;124(6):557-63. doi: 10.7326/0003-4819-124-6-199603150-00003
71. Berlowitz DR, Brandeis GH, Morris JN, et al. Deriving a risk-adjustment model for pressure ulcer development using the Minimum Data Set. *Journal of the American Geriatrics Society* 2001;49(7):866-71. doi: 10.1046/j.1532-5415.2001.49175.x
72. Poss J, Murphy KM, Woodbury MG, et al. Development of the interRAI Pressure Ulcer Risk Scale (PURS) for use in long-term care and home care settings. *BMC geriatrics* 2010;10:67. doi: 10.1186/1471-2318-10-67
73. Compton F, Hoffmann F, Hortig T, et al. Pressure ulcer predictors in ICU patients: nursing skin assessment versus objective parameters. *J Wound Care* 2008;17(10):417-20, 22-4. doi: 10.12968/jowc.2008.17.10.31304
74. Lowery MT. A pressure sore risk calculator for intensive care patients: 'the Sunderland experience'. *Intensive Crit Care Nurs* 1995;11(6):344-53. doi: 10.1016/s0964-3397(95)80452-8
75. Baldwin KM, Ziegler SM. Pressure ulcer risk following critical traumatic injury. *Advances in wound care : the journal for prevention and healing* 1998;11(4):168-73.

76. Bergquist S. Subscales, subscores, or summative score: evaluating the contribution of Braden Scale items for predicting pressure ulcer risk in older adults receiving home health care. *Journal of wound, ostomy, and continence nursing : official publication of The Wound, Ostomy and Continence Nurses Society* 2001;28(6):279-89. doi: 10.1067/mjw.2001.119012
77. Song M, Choi KS. Factors predicting development of decubitus ulcers among patients admitted for neurological problems. *The Journal of Nurses Academic Society* 1991;21(1):16-26.
78. Halfens R, Van Achterberg T, Bal R. Validity and reliability of the Braden scale and the influence of other risk factors: a multi-centre prospective study. *International Journal of Nursing Studies* 2000;37(4):313-19.
79. Choi KS, Song MS. Test of predictive validity for the new pressure risk assessment scale. *Journal of Korean Academy of Adult Nursing* 1991;3(1):19-28.
80. Kwong E, Pang S, Wong T, et al. Predicting pressure ulcer risk with the modified Braden, Braden, and Norton scales in acute care hospitals in Mainland China. *Appl Nurs Res* 2005;18(2):122-8. doi: 10.1016/j.apnr.2005.01.001
81. Pang SM, Wong TK. Predicting pressure sore risk with the Norton, Braden, and Waterlow scales in a Hong Kong rehabilitation hospital. *Nursing Research* 1998;47(3):147-53.
82. Schue RM, Langemo DK. Pressure ulcer prevalence and incidence and a modification of the Braden Scale for a rehabilitation unit. *Journal of wound, ostomy, and continence nursing : official publication of The Wound, Ostomy and Continence Nurses Society* 1998;25(1):36-43. doi: 10.1016/s1071-5754(98)90011-0
83. Austin PC, Steyerberg EW. Events per variable (EPV) and the relative performance of different strategies for estimating the out-of-sample validity of logistic regression models. *Stat Methods Med Res* 2017;26(2):796-808. doi: 10.1177/0962280214558972 [published Online First: 2014/11/19]
84. Smith GC, Seaman SR, Wood AM, et al. Correcting for optimistic prediction in small data sets. *Am J Epidemiol* 2014;180(3):318-24. doi: 10.1093/aje/kwu140 [published Online First: 2014/06/24]
85. Ramspek CL, Jager KJ, Dekker FW, et al. External validation of prognostic models: what, why, how, when and where? *Clin Kidney J* 2021;14(1):49-58. doi: 10.1093/ckj/sfaa188 [published Online First: 2020/11/24]
86. de Hond AAH, Shah VB, Kant IMJ, et al. Perspectives on validation of clinical predictive algorithms. *npj Digital Medicine* 2023;6(1):86. doi: 10.1038/s41746-023-00832-9
87. Binuya MAE, Engelhardt EG, Schats W, et al. Methodological guidance for the evaluation and updating of clinical prediction models: a systematic review. *BMC Med Res Methodol* 2022;22(1):316. doi: 10.1186/s12874-022-01801-8 [published Online First: 2022/12/12]
88. Qaseem A, Mir TP, Starkey M, et al. Risk Assessment and Prevention of Pressure Ulcers: A Clinical Practice Guideline From the American College of Physicians. *Annals of Internal Medicine* 2015;162(5):359-69. doi: 10.7326/m14-1567
89. Pei J, Guo X, Tao H, et al. Machine learning-based prediction models for pressure injury: A systematic review and meta-analysis. *Int Wound J* 2023 doi: 10.1111/iwj.14280 [published Online First: 2023/06/20]
90. Bossuyt PM, Reitsma JB, Bruns DE, et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. *BMJ* 2015;351:h5527. doi: 10.1136/bmj.h5527 [published Online First: 2015/10/28]
91. Moons KG, Altman DG, Reitsma JB, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. *Ann Intern Med* 2015;162(1):W1-73. doi: 10.7326/m14-0698
92. Hernandez-Boussard T, Bozkurt S, Ioannidis JPA, et al. MINIMAR (MINimum Information for Medical AI Reporting): Developing reporting standards for artificial intelligence in health care. *Journal of the American Medical Informatics Association* 2020;27(12):2011-15. doi: 10.1093/jamia/ocaa088

713 93. Collins G, Dhiman P, Logullo P, et al. TRIPOD+AI. OSF, 2023.